Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its ArcelisTM technology platform, was presented with the "2012 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's (SEBIO) 14th Annual Investor Forum on November 1, 2012 in Palm Beach, FL. B. Jefferson (Jeff) Clark, a member of Argos Therapeutics’ Board of Directors, accepted the award on the behalf of company.